Splash Beverage Group And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed lower by more than 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Applied Digital

• The Trade: Applied Digital Corporation APLD CEO, Chairman Wes Cummins acquired a total 25,000 shares an average price of $3.60. To acquire these shares, it cost around $90 thousand.
• What’s Happening: Applied Digital posted a narrower-than-expected quarterly loss.
• What Applied Digital Does: Applied Digital Corp designs, develops and operates next-generation datacenters across North America to provide digital infrastructure solutions to the rapidly growing high performance computing industry.

Splash Beverage Group

• The Trade: Splash Beverage Group, Inc. SBEV CEO and Chairman Robert Nistico acquired a total of 12,000 shares at an average price of $1.15. The insider spent around $13.79 thousand to buy those shares.
• What’s Happening: Splash Beverage posted a FY22 loss of $0.58 per share.
• What Splash Beverage Group Does: Splash Beverage Group Inc is a portfolio company managing multiple brands across several growth segments within the consumer beverage industry.

Check This Out: Wall Street's Most Accurate Analysts Say Sell These 3 Tech Stocks Delivering High-Dividend Yields

CNS Pharmaceuticals

• The Trade: CNS Pharmaceuticals, Inc. CNSP CEO John M Climaco acquired a total of 15,000 shares at an average price of $0.69. To acquire these shares, it cost around $10.41 thousand.
• What’s Happening: CNS Pharmaceuticals received approval from the Competent Authority and the central Ethics Committee in Italy for its potentially pivotal global trial evaluating Berubicin for the treatment of GBM.
• What CNS Pharmaceuticals Does: CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors.

Don’t forget to check out our premarket coverage here